A groundbreaking study by researchers from RMIT University in Australia and Indian institutions has unveiled a novel ...

A new gold-based drug can slow tumour growth in animals by 82% and target cancers more selectively than standard chemotherapy ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study. The results could potentially lead to new therapies ...

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

Scientists at Weill Cornell Medicine have uncovered a critical mechanism driving the growth of treatment-resistant prostate ...

A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...

Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of ...

Researchers explore how established agricultural pest management strategies could be adapted to address cancer therapy. The pioneering method opens new possibilities for controlling drug resistance ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

“This study reveals a critical mechanism behind treatment resistance in prostate cancer, suggesting new therapeutic approaches,” explained Diaz-Meco. “By understanding EZH2’s role in this context, we ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, ...